MedPath

Enhancing Social Functioning in Young People at Ultra High Risk for Psychosis: Randomised Controlled Trial of a Novel Strengths-based Online Social Therapy

Not Applicable
Recruiting
Conditions
ltra-high risk for psychosis
Ultra-high risk for psychosis
Mental Health - Psychosis and personality disorders
Registration Number
ACTRN12619001411134
Lead Sponsor
Orygen, the National Centre of Excellence in Youth Mental Health
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
220
Inclusion Criteria

1.Age 14 to 27 years inclusive;
2.Ability to read and converse in English;
3.Ability to provide informed consent;
4.Ability and willingness to nominate an emergency contact person, such as a close family member;
5.Meeting criteria for one or more UHR for psychosis groups (Vulnerability group, Attenuated Psychotic Symptoms group or Brief Limited Intermittent Psychotic Symptoms (BLIPS) group).

Exclusion Criteria

1.Past history of a psychotic episode of one week or longer;
2.Acute risk of self-harm requiring urgent intervention (i.e., suicidal ideation with a current plan and intent to enact this plan);
3.Inability to converse in, or read English;
4.Attenuated psychotic symptoms only present during acute intoxication.
5.Organic brain disease known to cause psychotic symptoms, e.g. temporal lobe epilepsy.
6.Any metabolic, endocrine or other physical illness, e.g. thyroid disease, with known neuropsychiatric consequences.
7.Diagnosis of a serious developmental disorder, e.g. Severe Autism Spectrum Disorder.
8.A documented history of developmental delay or intellectual disability.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Social functioning - This will be measured by the Global Functioning Social Scale, a valid and reliable instrument designed to measure social functioning in Ultra High Risk (UHR) young people (Cornblatt et al., 2007)[ Social functioning will be assessed at baseline and 4, 8, and 12 (primary timepoint) months post randomisation.]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath